Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

Fig. 1

Genetic alterations in NPC-PDX tumors. (a) Copy number variations (CNV) of NPC-PDX tumors versus corresponding patient’s peripheral blood mononuclear cells (PBMC). Genome-wide CNV alterations in four paired PDX tumor samples (ST, LN, LG and LV). CCND1 CNV gain (red arrow) and CDKN2A CNV loss (green arrow) are indicated. (b) HE and EB virus-encoded small RNA (EBER) staining of parental NPC tumor with bone metastasis and its derived NPC-PDX. (c) CNV profile comparisons of NPC FFPE-Bone and PDX-Bone based on WES and (d) ultra-deep sequencing of cancer panel-409 are shown (genes associated with or without copy number alteration are indicated in different colors or in grey, respectively). Observed copy number for each evaluated position is shown on the y-axis as a log 2 scale. Correlation plots with Pearson’s correlation coefficient, r, indicating similarities between two CNV profiles

Back to article page